Thrombocytopenia in patients with myelodysplastic syndromes: Still an unsolved problem

Keyphrases

• Myelodysplastic Syndrome 100%
• Thrombocytopenia 100%
• Safety Concerns 50%
• Platelet Count 50%
• Eltrombopag 50%
• Romiplostim 50%
• Life-threatening 25%
• Disease Progression 25%
• Monotherapy 25%
• Bone Marrow Cells 25%
• Liver Disease 25%
• Prognostic Marker 25%
• Bleeding Complications 25%
• Platelets 25%
• Low Platelet Count 25%
• No Evidence of Disease 25%
• Acute Leukemia 25%
• Cellular Dysfunction 25%
• Hematologic 25%
• Stimulating Agent 25%
• Bleeding Episodes 25%
• Hypomethylating Agents 25%
• Lenalidomide 25%
• Low-risk Myelodysplastic Syndromes 25%
• Thrombopoietin 25%
• Potential Transformation 25%
• Bone Marrow Blast 25%
• Stem Cell Deficiency 25%
• Thrombopoiesis 25%
• Immune Thrombocytopenia 25%
• Platelet Transfusion 25%
• Leukemic Transformation 25%
• High-risk Myelodysplastic Syndrome 25%
• Ineffective Hematopoiesis 25%
• Peripheral Cytopenia 25%

Medicine and Dentistry

• Myelodysplastic Syndrome 100%
• Thrombocytopenia 100%
• Platelet 75%
• Eltrombopag 50%
• Romiplostim 50%
• Liver Disease 25%
• Bleeding 25%
• Hematopoiesis 25%
• Monotherapy 25%
• Idiopathic Thrombocytopenic Purpura 25%
• Low Platelet Count 25%
• Analeptic 25%
• Acute Leukemia 25%
• Cloning 25%
• Disease Exacerbation 25%
• Disease 25%
• Lenalidomide 25%
• Hypomethylating Agent 25%
• Thrombocytopoiesis 25%
• Thrombocyte Transfusion 25%
• Thrombopoietin 25%
• Cytopenia 25%
• Hematopoietic Cell 25%